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Background: Women with borderline/mildly dyskaryotic (BMD) cytology smears are currently followed up with repeat testing at 6
and 18 months. The objective of this study is to analyse the cross-sectional and longitudinal performance of p16/Ki-67 dual-stained
cytology for the detection of cervical intraepithelial neoplasia (CIN) grade 3 or worse (CIN3þ ) and CIN2þ in women with BMD,
and to compare the results with baseline human papillomavirus (HPV) testing.
Methods: Conventional Pap cytology specimens of 256 women with BMD were dual stained for p16/Ki-67 retrospectively, and
compared with baseline HPV results and long-term follow-up results.
Results: p16/Ki-67 dual-stained cytology showed a sensitivity of 100%, a specificity of 64.4% and a negative predictive value (NPV)
of 100.% for CIN3þ . Human papillomavirus testing demonstrated similar sensitivity (96.3%), and NPV (99.1%), but a significantly
lower specificity (57.6%; P¼ 0.024) for CIN3þ . Sensitivity, specificity and NPV for CIN2þ of dual-stained cytology were 89.7%,
73.1% and 95.1%, respectively, which was similar when compared with HPV testing. Dual-stained cytology showed a significant
lower referral rate than HPV testing (43.6% vs 49.1%; P¼ 0.043). During long-term follow-up, no CIN3þ lesions developed in HPV-
positive, dual-stained negative women.
Conclusions: Comparable sensitivity and NPV of dual-stained cytology for CIN3þ , combined with a significantly higher
specificity, makes p16/Ki-67 dual-stained cytology a viable alternative to HPV testing for triaging BMD.
In the Netherlands cytology screening programme, B2–3% of
women are diagnosed with borderline/mildly dyskaryotic (BMD)
Pap cytology. (Health Council of the Netherlands, 2011; Denise
et al, 2001). Even though this percentage is relatively low compared
with other screening programs, it corresponds to almost 15 000
women per year. Because only 5–15% of these women have
high-grade cervical disease, further triage is necessary (Arbyn et al,
2006; Berkhof et al, 2006). Currently, women with BMD are
recalled for repeat cytology after 6 months, and if the cytological
abnormality persists they are referred for colposcopy-directed
biopsy. The disadvantage of repeat testing is that women may
become lost to follow-up (Lytwyn et al, 2003) and experience
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distress (Melnikow et al, 2002; Dietsch and Davies, 2007). By
testing women with BMD for the presence of human papilloma-
virus (HPV) results in a much higher sensitivity for the detection
of cervical intraepithelial neoplasia (CIN)2þ /3þ compared with
repeat Pap cytology testing, and consequently less follow-up visits
(Bulk et al, 2007; Bulkmans et al, 2007; Ronco et al, 2010; Kelly
et al, 2011; Kitchener et al, 2013). However, HPV testing has a
2–5% lower specificity for CIN2þ /3þ than cytology. Because of
this limited specificity, HPV triaging at baseline results in higher
colposcopy referral rates than repeat cytology.
Recently, cross-sectional studies have shown a significantly
higher specificity for p16/Ki-67 dual-stained cytology compared
with HPV triage, without a substantial loss of sensitivity for high-
grade cervical lesions (Denton et al, 2010; Schmidt et al, 2011;
Wentzensen et al, 2012). Normally, the p16 protein triggers cell
cycle arrest in the course of cellular differentiation processes and is
rarely observed simultaneously with Ki-67. However, in transform-
ing HPV infections, p16 is strongly overexpressed in proliferating
cells, and the p16-induced cell cycle arrest is circumvented by
inactivation of pRb, which is mediated by the expression of the
viral E7 oncoprotein of high-risk HPV types. Observing dual
expression therefore suggests HPV-induced deregulation of the cell
cycle and may be used as an indicator for the presence of CIN2þ /
3þ lesions (Schmidt et al, 2011; Loghavi et al, 2013; Waldstrom
et al, 2013).
The aim of this study was to evaluate the use of p16/Ki-67dual-
stained cytology as a triage test at baseline for identifying women
with BMD, and underlying CIN3þ and CIN2þ lesions within a
population-based screening setting with long-term follow-up
(VUSA-Screen study). The results of p16/Ki-67 dual-stained
cytology, which was performed on the original, de-stained
conventional Pap cytology specimens prepared at patient enrol-
ment into the VUSA-Screen study, were compared with the
baseline performance of the Hybrid Capture 2 (HC2) high-risk
HPV test. Furthermore, as one of the first studies, we examined the
long-term predictive values of the p16/Ki-67 dual staining for the
presence or absence of CIN3þ and CIN2þ lesions.
SUBJECTS AND METHODS
Study population. The study was conducted as a sub-study nested
in the VUSA-Screen study, a cohort study within the setting of the
Dutch population-based cervical cancer screening programme. The
VUSA-Screen study took place between 2003 and 2005. The study
was designed to evaluate the effectiveness of HPV testing using
the Digene HC2 assay (Qiagen, Venlo, The Netherlands) in a
population-based screening cohort. The design of the study has
been described previously (Rijkaart et al, 2010). In the intervention
arm of the VUSA-Screen study, women with BMD test results were
subjected to HPV triage testing. In case of HPV-positive test
results, women were directly referred to colposcopy. Women with
BMD and a negative HPV test result were offered cytology at 6 and
18 months and were referred to colposcopy upon abnormal
cytology (XBMD) during these follow-up visits (Figure 1).
In the sub-study reported here, we selected all archived
conventional cytology slides of the 337 women with BMD
participating in the intervention arm of the VUSA-Screen study.
We retrieved 305 of these slides for conducting p16/Ki-67 dual-
stained cytology, retrospectively. Histology and/or cytology follow-
up results were collected until December 2012, providing up to 9
years of follow-up. In this timeframe, all women should have had a
follow-up visit (i.e., more than a full round in population-based
screening). These follow-up results were retrieved from PALGA,
the nationwide registry and network of histological and cytological
results in the Netherlands (Casparie et al, 2007). The results of
HPV test triage and p16/Ki-67 triage were compared at baseline
and after the entire follow-up period. For each woman, the most
severe diagnosis during follow-up was used.
p16/Ki-67 dual-stained cytology. A commercial kit specifically
designed for the simultaneous detection of p16 and Ki-67 in
cervical cytology preparations was used (CINtec PLUS, Roche mtm
laboratories AG, Mannheim, Germany). All slides were de-stained
and subjected to p16/Ki-67 dual staining according to the
instructions of the manufacturer. All immunostained slides were
analysed and scored by an experienced cytotechnologist blinded to
all study data. Samples were considered positive when p16 and
Ki-67 immunoreactivities were revealed within the same cell (i.e., a
cytoplasmic brown staining for p16, together with a nuclear red
staining for Ki-67). The presence of at least one dual-stained cell(s)
was used as a cutoff to rate the sample as positive for the CINtec
PLUS test (Figure 2). As a sub-analysis, we also evaluated the
performance of p16/Ki-67 dual-stained cytology at cutoffs of 2–4,
5–49, and 50 or more dual-stained cells.
HPV detection. High-risk HPV testing was performed by HC2
high-risk HPV DNA test in an automated format on a rapid
capture system according to manufacturer’s instructions (Qiagen).
This test uses a cocktail probe to detect 13 high-risk HPV types: 16,
18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68. Samples with HC2
outcome ofX1 RLU/CO were considered as HPV positive. Results
of this analysis, which was carried out at baseline, were used for the
comparison with p16/Ki-67 dual-stained cytology in the current
study.
Cytology. From all women, a conventional cytological scrape was
taken with a cytobrush (Rovers, Oss, The Netherlands). After
preparation of the smear on a glass slide, the brush was placed in a
vial containing 1 ml Universal Collection Medium (Qiagen) for
HPV testing. Cervical cytology results were reported, blinded to the
HPV testing results, according to the CISOE-A classification based
on Dutch guidelines. This classification is a five-tiered cytology
classification system that can be easily converted into either the
British or the 2001 Bethesda system (Hanselaar, 2002). Borderline/
mildly dyskaryotic corresponds to atypical squamous cells of
undetermined significance, atypical squamous cells, and cannot
exclude high-grade squamous intraepithelial lesions or low-grade
squamous intraepithelial lesions. Moderate- or worse dyskaryosis
corresponds to high-grade squamous glandular intraepithelial
lesions.
Evaluation of the p16/Ki-67 dual-stained cytology results were
compared with the baseline results of the Pap cytology smears.
Histology. Of the women who were referred to colposcopy,
colposcopy-directed biopsies were taken from suspicious areas
from their cervix according to standard procedures in the
Netherlands (Hopman et al, 2000). Histological examination of
these biopsies was carried out at local pathology laboratories and
classified as normal, CIN grade 1, 2 or 3, or as invasive cancer
according to international criteria (Hopman et al, 1995; Anderson
2013). High-grade lesions were all reviewed by two independent
pathologists at the VU University Medical Center.
Data and statistical analysis. The association between p16/Ki-67
positivity, HPV positivity and CIN3þ lesions detected within 3
years of follow-up were tested using the w2-test. Cervical
intraepithelial neoplasia (CIN2þ ) was used as an additional,
secondary outcome. Adjusted estimates for sensitivity, specificity,
positive predictive value (PPV), negative predictive value (NPV)
and referral rates were calculated from cross-tabulation of test
results and adjusted end points. Significant differences between
tests with regard to sensitivity, specificity and referral rates were
calculated using the McNemar test. The two tests were compared
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with respect to PPV and NPV using the method of Leisenring et al
(2000). Exact 95% confidence intervals (CIs) were calculated.
Women reached their study-end point if they had a histological
outcome or an adjusted end point. Different adjusted end points
were defined for HPV-positive and HPV-negative women with
BMD, given their different risks of high-grade lesions (i.e.,
cumulative 3-year CIN3þ risk of 20.4% (HPV-positive women)
vs 1.3% (HPV-negative women); Rijkaart et al, 2010, Katki et al,
2013). For both HPV-positive and HPV-negative women with
BMD, the adjusted end point was defined as pCIN1 when they
had normal cytology and a negative HPV result as a repeat test.
Alternatively, HPV-positive BMD women were considered to have
pCIN1 when they had no HPV test result in follow-up but twice
normal cytology follow-up test results. The latter women have
a CIN3þ risk of 1.2% that is in the Netherlands sufficiently
low to dismiss them from further follow-up. As BMD women with
a HPV-negative result have a low intrinsic risk of high-grade
disease, they were already categorised as havingpCIN1 when they
had no HPV follow-up result, but had a single smear read as
normal cytology within 1 year after the BMD result. Women with
hrHPV neg
P16/Ki-67 pos
N =12
hrHPV neg
N =128
hrHPV pos
N =128
hrHPV neg
P16/Ki-67 neg
N =116
hrHPV pos
P16/Ki-67 pos
N =101
hrHPV pos
P16/Ki-67 neg
N =27
CIN1 35
CIN2 25
CIN3 26
Cancer 0
No end point   15
CIN1 16
CIN2 5
CIN3 0
Cancer 0
No end point   6
CIN1 8
CIN2 0
CIN3 1
Cancer 0
No end point   3
CIN1 101
CIN2 1
CIN3 0
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BMD
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BMD
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N =49
Not available
N =32
BMD
Direct referral to
colposcopy/biopsy
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at 6 and 18 months
Referral to colposcopy/
biopsy if cytology BMD
Retrospective p16/Ki-67 dual staining
Figure 1. Flowchart design of VUSA-Screen study including p16/Ki-67 dual-stain cytology test results in 256 women with BMD – 3-years
follow-up.
Figure 2. (A) Pap-stained BMD smear ( 40) without p16/Ki-67 dual staining. (B) The same smear as in picture A dual stained for p16/Ki-67. Brown
cytoplasmic signal for p16 overexpression and red nuclear signal for Ki-67 expression within the same cell points to dysplasia.
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other (combinations of) repeat-test results were considered as
having no adjusted end point and were therefore excluded from the
analysis.
For the long-term predictive value of both the p16/Ki-67 dual
staining and the HPV triage testing, the Kaplan–Meier analysis
with the log-rank test was carried out. All women in this study with
BMD were followed up until 9 years after inclusion. In this
timeframe, all women should have had a follow-up visit (i.e., more
than a full round in population-based screening).
Analyses were carried out with IBM SPSS version 20
(International Business Machines Corp., Armonk, NY, USA).
RESULTS
Study population. Of the 337 women with BMD who participated
in the VUSA-Screen study, a total of 305 archived conventional
cytological slides were available for p16/Ki-67 dual-stained
cytology. Following removal of the original cover slide by xylene
treatment and subsequent de-staining, slides were stained in two
separate, subsequent sets. There were 49 out of the 305 cases
excluded from the analysis, as these slides were not evaluable.
Owing to inhomogeneous staining, 25 (51%) cases were excluded
and 17 (35%) cases were excluded because of background staining.
Furthermore, five slides (10%) were broken during processing and
two (4%) slides had a very low cellularity. Forty-three out of these
49 slides (88%) were stained as part of the initial staining set.
A total of 256 cases were included in the final analysis.
Patients’ characteristics. The median age of the women included
in this study was 40.0 years (range 29–60 years). Half of the women
were HC2 high-risk HPV positive (128/256, 50.0%), whereas the
remaining 128 women tested HPV negative. Among the women
who attended a follow-up visit, the median follow-up time was 61
months (range 1–103 months). For this analysis, 106/128 (82.8%)
of the HPV-positive women had a histological end point.
One HPV-positive woman, having normal cytology and a negative
HPV test, was considered to havepCIN1 as an adjusted end point.
For the remaining 21 women, no adjusted end points could be
determined. Seven of them (7/128; 5.5%) did not have any follow-
up test result between inclusion and 3 years later. Another 12
women (9.4%) had one normal cytology follow-up test result
without information about their HPV status. They did not meet
the criteria for an adjusted end point and were excluded. Finally,
two women had a BMD smear as follow-up outcome (1.6%) and
thus no adjusted end point as well.
Of the 128 HPV-negative women with BMD, 20 women (15.6%)
had a histological end point. Adjusted end points (pCIN1) could
be established for 91 other HPV-negative women (71.1%); 20 of
them based on a double-negative cytology and HPV test result in
follow-up, and 71 of them because of a repeat normal cytology test
result in follow-up. For the remaining 17 women, no adjusted end
points were determined. Fourteen of them did not have any follow-
up test result (11.0%) between inclusion and 3 years later. Another
three women (2.0%) had a BMD outcome during follow-up.
p16/Ki-67 positivity rates. The overall p16/Ki-67 positivity for
women with and without an end point was 44.1% (113/256).
The main outcomes between the different groups are presented
in Figure 1.
There was a significant trend (Po0.001) for p16/Ki-67 dual-
staining positivity and increasing severity of disease: positivity
varied from 44.1% (15/34) in women without dysplasia, 58.8%
(20/34) in women with CIN1, 80.6% (25/31) in CIN2 to 100.0%
(27/27) in women with CIN3. The prevalence of positive p16/Ki-67
test results in the HPV-positive group was 78.9% vs 9.4% in the
HPV-negative cohort.
Sensitivity and specificity of p16/Ki-67 dual-stained cytology in
comparison with HPV testing results. Sensitivities, specificities,
PPVs and NPVs as well as referral rates were calculated for p16/Ki-
67 and HPV (Table 1).
Table 1. Clinical performance of p16/Ki-67 and HPV testing to detect CIN2þ or CIN3þ in women with BMD using the standard positivity cutoff
of X1 dual-stained cell in the first half and alternative cutoffs in the second half
n1/N1 Sensitivity (95% CI) n2/N2 Specificity (95% CI) PPV (95% CI) NPV (95% CI)
Referral
rate
p16/Ki-67 X1 pos
CIN2þ 52/58 89.7% 78.8–96.1% 117/160 73.1% 65.6–79.8% 54.7% 44.2–65.0% 95.1% 89.7–98.2%
CIN3þ 27/27 100.0% 87.2–100.0% 123/191 64.4% 57.2–71.2%a 28.4% 19.6–38.6%a 100.0% 97.0–100.0% 43.6%a
hrHPV
CIN2þ 56/58 96.6% 88.1–99.6% 109/160 68.1% 60.3–75.3% 52.3% 42.5–62.1% 98.2% 93.6–99.8%
CIN3þ 26/27 96.3% 81.0–99.9% 110/191 57.6% 50.2–64.7% 24.3% 16.5–33.5% 99.1% 95.1–100.0% 49.1%
Alternative cutoffs
p16/Ki-67 X2 pos
CIN2þ 51/58 87.9% 76.7–95.0% 120/160 75.0% 67.6–81.5% 56.0% 45.2–66.4% 94.5% 89.0–97.8%
CIN3þ 26/27 96.3% 81.0–99.9% 126/191 66.0% 58.8–72.7% 28.6% 19.6–39.0% 99.2% 96.3–100.0% 41.7%
p16/Ki-67 X5 pos
CIN2þ 45/58 77.6% 64.7–87.5% 134/160 83.8% 77.1–89.1% 63.4% 51.1–74.5% 91.2% 85.4–95.2%
CIN3þ 26/27 96.3% 81.0–99.0% 146/191 76.4% 69.8–82.3% 36.6% 25.5–48.9% 99.3% 96.3–100.0% 32.6%
p16/Ki-67 X50 pos
CIN2þ 24/58 41.4% 28.6–55.1% 151/160 94.4% 89.6–97.4% 72.7% 54.5–86.7% 81.6% 75.3–86.9%
CIN3þ 15/27 55.6% 35.3–74.5% 173/191 90.6% 85.5–94.3% 45.5% 28.1–63.6% 93.5% 88.9–96.6% 15.1%
Abbreviations: CI¼ confidence interval; CIN¼ cervical intraepithelial (grade 2 or 3 or higher); HPV¼human papillomavirus; n1¼ number of test positive disease cases; N1¼ total number of
disease cases; n2¼ number of test negative non-disease cases; N2¼ total number of non-disease cases; NPV¼ negative predictive value; PPV¼positive predictive value.
aSignificant difference compared with HPV (Po0.05).
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For CIN3þ , the sensitivity of p16/Ki-67 dual-stained cytology
was similar to HPV testing (100.0% vs 96.3%; P¼ 1.00). Also for
CIN2þ , sensitivity of both tests were similar (89.7% vs 96.6%;
P¼ 0.219).
Specificity of p16/Ki-67 for CIN3þ was significantly higher in
comparison with HPV testing (64.4% vs 57.6%; P¼ 0.024). Also,
the PPV of p16/Ki-67 dual-stained cytology was higher at the
CIN3þ threshold (28.4% vs 24.3%; P¼ 0.013). For CIN2þ , the
specificity for p16/Ki-67 dual-stained cytology was comparable to
HPV testing (73.1 and 68.1%; P¼ 0.08). Also, the PPVs for
CIN2þ were similar (54.7 and 52.3%; P¼ 0.396) (Table 1).
Referral rates of BMD women on the basis of p16/Ki-67 dual-
stained cytology would have resulted in lower referral rates of these
women for colposcopy (43.6% vs 49.1%; P¼ 0.043) compared with
referral on the basis of HPV testing.
Long-term follow-up data. The 5-year cumulative incidence risks
(CIRs) of the BMD women stratified by p16/Ki-67 dual-stained
cytology results, HPV results or both, are presented in Table 2
with corresponding Kaplan–Meier curves for CIN2þ and CIN3þ
in Figure 3.
Women with a BMD test result at baseline and a negative HPV
test had a 5-year CIR of 0.8% (95% CI 0.0–2.4%) for CIN3þ ,
whereas in those with a negative p16/Ki-67 dual-stain test result no
CIN3 lesions were found. When analysed for CIN2þ outcome,
women with BMD and a negative HPV test had a 5-year CIR of
1.6%, whereas for those with a negative p16/Ki-67 test result, the
five-year CIR was 4.3% (95% CI: 1.0–7.6%). These risks were not
significantly different (P¼ 0.326).
The highest 5-year CIR was found for women with BMD and a
positive HPV, as well as a positive p16/Ki-67 dual-stained cytology
test result. For CIN3þ this risk was 26.9% (95% CI: 18.1–35.7%)
and for CIN2þ this risk was 53.3% (95% CI: 43.7–63.7%). Lowest
5-year CIRs were achieved for women with a negative HPV and a
negative p16/Ki-67 dual-stain result. For CIN2þ , this CIR was
0.9% (0.0–2.7%).
The 5-year CIR for CIN2þ for women with BMD, a positive
HPV test and a negative p16/Ki-67 dual-stained cytology result was
18.8% (95% CI: 3.9–33.7%). A negative HPV test and a positive
p16/Ki-67 dual-stained cytology result gave a 5-year CIR of 9.1%
(0.0–26.2%) for CIN2þ .
p16/Ki-67 dual-stained cytology testing at different cutoffs. In
all previous studies, a cutoff of ‘one or more’ dual-stained-positive
cells was applied for calling a slide positive for the p16/Ki-67
dual-stained cytology test. This threshold was also used in this
study. In addition, we tested the effects of raising the positivity
threshold on the sensitivity and specificity.
Raising the cutoff to two or more dual-stained-positive cells
resulted in an almost similar specificity for CIN3þ (66.0%) and
CIN2þ (75.0%) compared with a cutoff of one or more dual-
stained-positive cells. At this cutoff, one CIN3 lesion and seven
CIN2 lesions were missed. Raising the cutoff further to five or
more positive cells resulted in an increased specificity for CIN3þ
(76.4%) and CIN2þ (83.8%). However, although at this cutoff, no
more CIN3 lesions were missed compared with a cutoff of two or
more dual-stained-positive cells or compared with HPV triaging,
the sensitivity for CIN2þ was reduced (77.6%). Details of this
analysis are shown in Table 1.
DISCUSSION
This is one of the first studies that evaluates both the cross-
sectional and the longitudinal performance of p16/Ki-67 dual-
stained cytology as a triage tool for women with BMD compared
with HPV testing. Results indicate that for triaging women with
BMD cytology, p16/Ki-67dual staining, even on conventional
slides, has a small but significantly higher specificity for CIN3þ
than HPV testing (64.4% vs 57.6%). For both tests, the sensitivity
for CIN3þ was similar (100.0% vs 96.3%). At CIN2þ level, p16/
Ki-67 dual staining and HPV testing reached similar specificity
(73.1% vs 68.1%) and similar sensitivity (89.7% vs 96.6%) levels. In
addition, the results show that fewer women would be referred to
colposcopy in case of dual staining compared with HPV testing
(43.6% vs 49.1%).
Our results are generally comparable with data from other
cross-sectional studies (Schmidt et al, 2011; Wentzensen et al,
2012; Waldstrom et al, 2013), which have demonstrated that p16/
Ki-67 dual staining is superior to HPV testing at baseline with
respect to specificity and similar in terms of sensitivity for CIN3þ
and CIN2þ . Wentzensen et al (2012) showed that the specificity
of p16/Ki-67 dual staining for CIN2þ and CIN3þ was
significantly improved compared with HPV testing. In this study,
differences in specificity were only significant for CIN3þ . The
p16/Ki-67 detection rate for CIN2 was 80.6% (25/31). Six CIN2
detected within 3 years after baseline were negative for p16/Ki-67
at baseline. It is unclear whether these represent regressive or
persistent lesions. In comparison, there was only one woman with
CIN2 who tested negative for HPV at baseline. Mesher et al (2013)
compared different triage strategies, including p16 cytology among
Table 2. Cumulative 5-year incidence risks stratified by p16/Ki-67 dual-stained cytology (cutoff X1 dual-stained cell) or HPV or both
Baseline group
Number of
women CIR CIN3þ t¼60 95% CI CIR CIN2þ t¼60 95% CI
BMD p16/Ki-67 pos 113 25.2% 17.0–33.4 49.6% 40.0–59.2
BMD p16/Ki-67 neg 143 0.0% 4.3% 1.0–7.6
BMD HPV pos 128 21.1% 13.8–28.4 46.2% 37.4–55.0
BMD HPV neg 128 0.8% 0.0–2.4 1.6% 0.0–4.0
BMD HPV pos p16/Ki-67 pos 101 26.9% 18.1–35.7 53.7% 43.7–63.7
BMD HPV pos p16/Ki-67 neg 27 0.0% 18.8% 3.9–33.7
BMD HPV neg p16/Ki-67 pos 12 9.1% 0.0–26.2 9.1% 0.0–26.2
BMD HPV neg p16/Ki-67 neg 116 0.0% 0.9% 0.0–2.7
BMD total 256 11.0% 7.1–14.9 24.1% 18.8–29.4
Abbreviations: BMD¼borderline/mildly dyskaryosis; CI¼ confidence interval; CIR¼ cumulative incidence risk; CIN¼ cervical intraepithelial neoplasia (grade 2 or 3); HPV¼ human
papillomavirus; neg¼negative; pos¼positive; t¼ follow-up time in months.
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women who were referred for colposcopy with low-grade cytology.
For CIN2þ as well as CIN3þ , that study also found an improved
specificity for p16 cytology compared with HPV testing (for
CIN2þ , 50.7% vs 23.3%). They also reported the disadvantage of
missed lesions (for CIN3þ : 15–30%), where they advised early
recall for women with a negative test result for p16. One possibility
why in this study the specificity for p16/Ki-67 dual staining was
only significant for CIN3þ might be an overcall of CIN2 lesions
on biopsies.
To estimate the utility of p16/Ki-67 dual staining as a triage test,
we should also compare results with present cytology triage in the
5-year based screening programme, where a remaining risk of
CIN3þ of 1.2% is regarded to be acceptable for women with BMD
at baseline, and normal cytology at 6 and 18 months follow-up
(Rijkaart et al, 2012b). In this study, none of the women with BMD
and a negative dual-stained cytology result developed CIN3þ over
a period of up to 9 years. However, the 5-year cumulative CIN2þ
incidence risk of a woman with BMD and a negative dual-stain
result was 4.3% (95% CI: 1.0–7.6%) compared with 0.8% (95% CI:
0.0–2.4%) in women with BMD and a negative HPV test result.
Because in clinical practice women with a CIN2þ lesion require
treatment, we would advise women with BMD cytology and a
negative p16/Ki-67 dual staining result to attend a follow-up visit
within 2 years.
In order to determine the utility of the dual staining, more
considerations can be made. p16/Ki-67 dual staining should not
require morphological interpretation. This is an improvement of
the evaluation of p16 alone, which is still morphology dependent.
However, a trained cytotechnologist or pathologist will also be
influenced by the morphology as it is their expertise. Therefore,
in contrast to the HPV test, the evaluation of the dual staining is
not totally objective. It is a consideration of the clinician whether a
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Figure 3. (A) Cumulative incidence risk (CIR) of CIN3þ in women with BMD Pap cytology stratified by p16/Ki-67 dual-stained cytology or HPV
or both. (B) Cumulative incidence risk (CIR) of CIN2þ in women with BMD Pap cytology stratified by p16/Ki-67 dual-stained cytology or HPV or
both. For comparison, the cumulative disease in the whole cohort is also shown. BMD¼borderline/mildly dyskaryotic cytology smears;
HPV¼human papillomavirus; CIN2þ ¼ cervical intraepithelial neoplasia grade 2 or worse.
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cell-based triage with p16/Ki-67 with 5.5% less referrals or an
objective molecular HPV test with a somewhat higher referral rate
is preferred.
The New Technologies for Cervical Cancer Screening trial
investigated the usefulness of an earlier version of the p16 cytology
test for triaging HPV-positive women that was based on the p16
biomarker only (i.e., no p16/Ki-67 dual staining) in combination
with morphology interpretation of immunoreactive cells (Carozzi
et al, 2013). The authors concluded that p16 testing could be used
as a triage test for HPV-positive women and advised that HPV-
positive women with a negative p16 cytology test result should be
re-screened after 2–3 years, given a 3-year CIN2þ risk of 5.2%
(95% CI: 3.4–7.0%). Our data are similar to The New Technologies
for Cervical Cancer Screening at the CIN3þ threshold, but a
relevant number of CIN2 lesions remained undetected by p16/Ki-
67 dual-stained cytology. This leads to a 5-year CIR for CIN2þ of
18.8% among HPV-positive women with BMD. Therefore, a
follow-up of HPV-positive, p16/Ki-67 dual-stained cytology
negative women with initial BMD cytology results after 2 years
appears to be more appropriate based on the data of this study.
Currently, the p16/Ki-67 dual staining cutoff is one or more
dual-stained-positive cells. As reading p16/Ki-67 staining cells
requires experienced cytotechnicians/pathologists, and in order to
achieve a higher reproducible cutoff, we also evaluated the
performance of p16/Ki-67 dual-stained cytology at different
cutoffs. We measured a higher specificity for CIN2þ and CIN3þ
(83.8% and 76.4%) at a p16/Ki-67 positivity cutoff of five or more
dual-stained-positive cells when used in this BMD cohort. At this
cutoff, one CIN3 lesion and seven more CIN2 lesions would have
been missed when compared with using a cutoff of one or more
dual-stained cells. Therefore, given the high number of missed
CIN2 lesions and one CIN3 lesions that is missed, we did not
consider adjustment of the cutoff as improvement.
The strengths of this study were the large sample size, the long
follow-up of up to 9 years and the setting within a population-
based screening programme. An important limitation of this study
was the inability to assess 49 out of 305 samples due to
inhomogeneous re-staining or background staining of these
conventional smears.
Dual staining of the conventional Pap cytology slides in this
study was performed using a de-staining and dual-staining
protocol of two separate slide sets, in each of which about half of
the samples were stained. The de-staining protocol step of the
conventional slides in the initial set of slides processed may have
been too long, which led to excessive background staining. In that
initial set, 43 of the total of 49 non-evaluable slides were present.
In the second set, an optimisation of the de-staining protocol step
with respect to the length of the de-staining procedure was
implemented to prevent avoidable background staining, and thus
inadequate staining results. Because the two batches were blindly
assembled, we have no indication that re-staining had a biasing
effect on our outcomes. Also, the sensitivity and specificity for the
two batches were similar. It is important to note that these initial
technical issues related to the de-staining protocol are specific
study-related limitations owing to the use of archived, Pap-stained
conventional smears that are not applicable in routine clinical
practice, where either liquid-based cytology or co-collected
conventional smears or fresh Pap-stained conventional smears
might be used.
At last, there is a possibility of verification bias as, because of the
study protocol, not all of the 256 women had a histological end
point. Although studies have shown that a negative HPV test and
normal cytology is associated with an extremely low risk for
CIN3þ (Cuzick et al, 2006; Bulkmans et al, 2007; Mayrand et al,
2007; Dillner et al, 2008; Rijkaart et al, 2012a), we cannot exclude
yet that this may have biased our estimations (Ransohoff and
Feinstein, 1978; Choi, 1992).
In summary, our study shows that women with BMD cytology
result can be triaged with p16/Ki-67 dual-stained cytology testing,
with less referrals compared with HPV triage testing. Based on the
cumulative 5-year CIN2þ risk of 4.3% for women with BMD Pap
cytology that show negative p16/Ki-67 dual-stain results, we advise
these women to a follow-up visit within 2 years.
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